InFlectis BioScience
Private drug discovery company aiming at targeting.
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | (68687 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (60766 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
InFlectis BioScience is a clinical-stage biotechnology company based in France, dedicated to developing therapeutics that leverage the Integrated Stress Response (ISR) pathway. The company is currently focused on creating treatments for Charcot-Marie-Tooth (CMT) disease, a hereditary neurological disorder. InFlectis BioScience's business model revolves around advancing its drug candidates through clinical trials, with the aim of achieving regulatory approval and subsequent commercialization. Revenue generation is anticipated through partnerships, licensing agreements, and eventual product sales. The company has successfully completed Phase 1 clinical trials for its oral drug candidate, IFB-088, and is preparing to initiate Phase 2 studies. InFlectis BioScience operates within the pharmaceutical and biotechnology sectors, targeting healthcare providers and patients affected by diseases linked to ISR dysregulation. The company's strategic focus on ISR modulation positions it to address unmet medical needs across a range of conditions.
Keywords: Integrated Stress Response, therapeutics, Charcot-Marie-Tooth, clinical trials, biotechnology, drug development, neurological disorders, ISR modulation, healthcare, France.